Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
48 participants
INTERVENTIONAL
2009-07-31
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiple Ascending Dose Study for AZD 7268 in Japanese Healthy Male Volunteers
NCT01116011
AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects
NCT00769899
AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects
NCT00935025
To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects
NCT00738322
AZD2624 Multiple Ascending Dose Study in Japan
NCT00696865
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Low dose or placebo, twice daily
AZD7325
oral capsule, once or twice daily, 7 days
Placebo
oral capsule, once or twice daily, 7 days
2
Low dose or placebo, once daily
AZD7325
oral capsule, once or twice daily, 7 days
Placebo
oral capsule, once or twice daily, 7 days
3
Middle dose or placebo, twice daily
AZD7325
oral capsule, once or twice daily, 7 days
Placebo
oral capsule, once or twice daily, 7 days
4
High dose or placebo, once daily
AZD7325
oral capsule, once or twice daily, 7 days
Placebo
oral capsule, once or twice daily, 7 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD7325
oral capsule, once or twice daily, 7 days
Placebo
oral capsule, once or twice daily, 7 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Enrollment in another concurrent investigational study or intake of an investigational drug within 4 months prior to the screening visit
* Blood loss in excess of 200 mL within 30 days of Day 1, in excess of 400 mL within 90 days of Day 1, or in excess of 1200 mL within 1 year of Day 1
* Clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, hematology or urinalysis as judged by the investigator and/or sponsor
20 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuji Kumagai, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Kitasato University East Hospital, Kanagawa, Japan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1140C00015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.